{
  "metadata": {
    "version": "1.0",
    "last_updated": "2025-01-20",
    "reference": "PMC10730242",
    "description": "Reference data for atherosclerosis endotype prediction"
  },
  "endotypes": {
    "1": {
      "name": "Endotype 1 - Low Risk",
      "hazard_ratio": {
        "mi_risk": 1.0,
        "confidence_interval_lower": null,
        "confidence_interval_upper": null,
        "p_value": "reference"
      },
      "characteristics": {
        "il6r_range": "< 1500 pg/mL",
        "hspb1_range": "< 2000 pg/mL",
        "inflammatory_profile": "Minimal",
        "risk_level": "Low"
      },
      "pathways": [
        "Baseline inflammatory state",
        "Normal vascular function",
        "Minimal oxidative stress",
        "Intact endothelial barrier"
      ],
      "clinical_features": [
        "Lowest cardiovascular event rate",
        "Optimal biomarker profile",
        "Standard risk factor management indicated"
      ]
    },
    "2": {
      "name": "Endotype 2 - Low-Moderate Risk",
      "hazard_ratio": {
        "mi_risk": 2.1,
        "confidence_interval_lower": 1.5,
        "confidence_interval_upper": 2.9,
        "p_value": 0.001
      },
      "characteristics": {
        "il6r_range": "1500-2500 pg/mL",
        "hspb1_range": "2000-2800 pg/mL",
        "inflammatory_profile": "Mild",
        "risk_level": "Low-Moderate"
      },
      "pathways": [
        "IL6R-mediated inflammation",
        "JAK-STAT signaling activation",
        "Acute phase response",
        "Endothelial activation",
        "Leukocyte adhesion"
      ],
      "clinical_features": [
        "Elevated IL6R signaling",
        "Mild systemic inflammation",
        "Enhanced anti-inflammatory therapy may be beneficial"
      ]
    },
    "3": {
      "name": "Endotype 3 - Moderate-High Risk",
      "hazard_ratio": {
        "mi_risk": 3.5,
        "confidence_interval_lower": 2.7,
        "confidence_interval_upper": 4.5,
        "p_value": 0.0001
      },
      "characteristics": {
        "il6r_range": "Variable",
        "hspb1_range": "> 3000 pg/mL",
        "inflammatory_profile": "Moderate-High",
        "risk_level": "Moderate-High"
      },
      "pathways": [
        "Heat shock protein response activation",
        "Cellular stress pathways",
        "TNF-α signaling",
        "Oxidative stress response",
        "Protein folding stress",
        "ER stress response",
        "Apoptotic signaling"
      ],
      "clinical_features": [
        "Significant HSPB1 elevation",
        "Cellular stress response activation",
        "Aggressive risk factor modification needed"
      ]
    },
    "4": {
      "name": "Endotype 4 - Very High Risk",
      "hazard_ratio": {
        "mi_risk": 5.2,
        "confidence_interval_lower": 4.1,
        "confidence_interval_upper": 6.8,
        "p_value": 0.00001
      },
      "characteristics": {
        "il6r_range": "> 2500 pg/mL",
        "hspb1_range": "> 3500 pg/mL",
        "inflammatory_profile": "Severe",
        "risk_level": "Very High"
      },
      "pathways": [
        "Multi-pathway inflammatory activation",
        "IL6R/JAK-STAT signaling hyperactivation",
        "HSPB1-mediated stress response",
        "TNFR1 activation",
        "NF-κB pathway activation",
        "Systemic endothelial dysfunction",
        "Advanced plaque instability",
        "Matrix metalloproteinase activation",
        "Thrombotic pathway activation"
      ],
      "clinical_features": [
        "Multiple inflammatory pathways activated",
        "Highest cardiovascular event rate",
        "Maximal medical therapy indicated",
        "Consider novel therapeutic approaches"
      ]
    }
  },
  "biomarkers": {
    "il6r": {
      "full_name": "Interleukin-6 Receptor",
      "unit": "pg/mL",
      "function": "Mediates IL-6 inflammatory signaling",
      "clinical_significance": "Marker of systemic inflammation and cardiovascular risk",
      "pathway": "JAK-STAT signaling, acute phase response"
    },
    "hspb1": {
      "full_name": "Heat Shock Protein Beta-1 (HSP27)",
      "unit": "pg/mL",
      "function": "Cellular stress response and protein folding",
      "clinical_significance": "Elevated in response to cellular stress, oxidative damage",
      "pathway": "Stress response, apoptosis regulation, cytoskeletal stabilization"
    },
    "tnfr1": {
      "full_name": "Tumor Necrosis Factor Receptor 1",
      "unit": "pg/mL",
      "function": "TNF-α signaling mediator",
      "clinical_significance": "Inflammation and apoptosis signaling",
      "pathway": "NF-κB activation, inflammatory cytokine cascade"
    },
    "crp": {
      "full_name": "High-sensitivity C-Reactive Protein",
      "unit": "mg/L",
      "function": "Acute phase reactant",
      "clinical_significance": "General marker of systemic inflammation",
      "pathway": "Complement activation, innate immunity"
    }
  },
  "treatment_implications": {
    "endotype_1": [
      "Standard guideline-directed medical therapy",
      "Regular cardiovascular risk assessment",
      "Lifestyle modifications",
      "Routine lipid management"
    ],
    "endotype_2": [
      "Intensified statin therapy",
      "Monitor inflammatory markers",
      "Consider anti-inflammatory agents in select cases",
      "Optimize diabetes and hypertension control"
    ],
    "endotype_3": [
      "Aggressive lipid-lowering therapy",
      "Consider PCSK9 inhibitors",
      "Evaluate for secondary prevention strategies",
      "Close cardiovascular monitoring",
      "Cardiology referral recommended"
    ],
    "endotype_4": [
      "Maximal medical therapy",
      "Consider novel anti-inflammatory therapies (IL-6 inhibitors, colchicine)",
      "Evaluate for coronary imaging",
      "Clinical trial enrollment consideration",
      "Frequent cardiology follow-up",
      "Aggressive management of all modifiable risk factors"
    ]
  },
  "pathway_details": {
    "il6_jak_stat": {
      "name": "IL-6/JAK-STAT Signaling",
      "description": "Promotes inflammatory gene expression and acute phase response",
      "targets": ["IL6R", "JAK1/2", "STAT3"],
      "therapeutic_implications": "Potential target for anti-IL6R therapy (tocilizumab)"
    },
    "heat_shock_response": {
      "name": "Heat Shock Protein Response",
      "description": "Cellular protection against stress, but chronic elevation indicates ongoing damage",
      "targets": ["HSPB1", "HSP70", "HSP90"],
      "therapeutic_implications": "Reflects cellular stress burden, target for antioxidant therapy"
    },
    "tnf_signaling": {
      "name": "TNF-α Signaling",
      "description": "Pro-inflammatory cytokine pathway associated with atherosclerosis",
      "targets": ["TNFR1", "NF-κB", "MAPK"],
      "therapeutic_implications": "Potential for TNF inhibition in select high-risk cases"
    }
  }
}
